Search research articles
Contact Us
Filters
Showing results (181-190 of 193) with videos related to
Page
of 20
Sort By:
EMBO Molecular Medicine
|
April 5, 2012
P-selectin genotype is associated with the development of cancer cachexia
Benjamin H L Tan, Torill Fladvad, Theodore P Braun, et al.
Nature
|
February 9, 1999
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Y Y Kong, H Yoshida, I Sarosi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 31, 1999
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
H Hsu, D L Lacey, C R Dunstan, et al.
Journal of Internal Medicine
|
January 14, 2018
The challenges and possibilities of public access defibrillation
M Ringh, J Hollenberg, T Palsgaard-Moeller, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
November 30, 2016
New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss
Neil Johns, Cynthia Stretch, Benjamin H L Tan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 4, 2000
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li, I Sarosi, X Q Yan, et al.
Cell
|
May 6, 1998
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
D L Lacey, E Timms, H L Tan, et al.
Cell
|
April 18, 1997
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
W S Simonet, D L Lacey, C R Dunstan, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
June 18, 2021
Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
W P Te Rijdt, E T Hoorntje, R de Brouwer, et al.
ESMO Open
|
September 17, 2024
Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
R Sundar, D K A Chia, J J Zhao, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 193) with videos related to
Sort By:
Page
of 20
EMBO Molecular Medicine
|
April 5, 2012
P-selectin genotype is associated with the development of cancer cachexia
Benjamin H L Tan, Torill Fladvad, Theodore P Braun, et al.
Nature
|
February 9, 1999
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Y Y Kong, H Yoshida, I Sarosi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 31, 1999
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
H Hsu, D L Lacey, C R Dunstan, et al.
Journal of Internal Medicine
|
January 14, 2018
The challenges and possibilities of public access defibrillation
M Ringh, J Hollenberg, T Palsgaard-Moeller, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
November 30, 2016
New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss
Neil Johns, Cynthia Stretch, Benjamin H L Tan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 4, 2000
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li, I Sarosi, X Q Yan, et al.
Cell
|
May 6, 1998
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
D L Lacey, E Timms, H L Tan, et al.
Cell
|
April 18, 1997
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
W S Simonet, D L Lacey, C R Dunstan, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
June 18, 2021
Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
W P Te Rijdt, E T Hoorntje, R de Brouwer, et al.
ESMO Open
|
September 17, 2024
Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
R Sundar, D K A Chia, J J Zhao, et al.
Page
of 20